Hydroxychloroquine is effective in treating COVID-19 patients, according to new research conducted by the Henry Ford Health System. The study was published on the 1st of July, and it is already peer-reviewed. The researchers have made tests on approximately 2500 hospitalized patients in six different hospitals, as declared by Dr. Marcus Zervos, the head of the infectious disease working at the Henry Ford Health System.
The primary reason that he decided to take in this study was the fact that hydroxychloroquine proved to bring a couple of benefits, and the researchers wanted to know an exact extent to which it can be used. Zervos declared that the findings of the study are not only crucial for doctors but also for patients since there is no other option available in fighting the deadly virus.
According to Zervos, the conclusions of the study showed that hydroxychloroquine has a tremendous impact on reducing the death rate caused by COVID-19. When treated with hydroxychloroquine, only 13% of the patients died, compared to the average that is 26.4%.
Henry Ford Health System has recently published an article where it is stated that other present diseases also cause many of the fatalities. Amongst them, the most deadly diseases include lung and kidney complications.
Another part of the study includes analyzing the benefits of azithromycin in treating COVID-19 patients. The results showed that the mortality rate reached 20.1% when patients were treated with both substances, compared to only 22.4% when the only azithromycin was involved and 26.4% when none of the elements were involved.
Consequently, Zervos announced that at the moment, more tests should be completed to determine the effectiveness of this treatment. Until then, both azithromycin and hydroxychloroquine should be used only under medical surveillance. After all, hydroxychloroquine is mainly used for malaria and lupus patients, and the only reason that it became so popular was owed to Trump’s declarations, which went against FDA’s warnings.